All In MedTech

Device Trial Radar · NCT04341298

Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

Clinical Evaluation of Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

Last checked: Nov 19, 2026Latest source record: Jan 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Apr 6, 2020

Primary completion

Aug 26, 2020

Study completion Aug 26, 2020

Sponsor

Lead sponsor
Avulux, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Imarc Research, Inc.
First posted
Apr 10, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application, when compared to a control device.

Conditions

  • Migraine

Interventions

  • 11-point pain scaleOther

    Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.

  • Headache diaryOther

    Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.

  • Avulux®Device

    Avulux® device

  • Sham Avulux®Device

    Sham Avulux®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in 11-point Pain Scale Score After Two Hours (First Severe Headache)Time frame: from baseline to 2 hours after device application

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Institute, Inc.

    Minneapolis, Minnesota

  • Endocrinology Research Associates, Inc.

    Columbus, Ohio

  • Remington-Davis Clinical Research

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.